Amgen Inc. $AMGN Shares Acquired by Ellsworth Advisors LLC

Ellsworth Advisors LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 6.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,941 shares of the medical research company’s stock after purchasing an additional 1,669 shares during the quarter. Amgen comprises 1.7% of Ellsworth Advisors LLC’s investment portfolio, making the stock its 11th largest holding. Ellsworth Advisors LLC’s holdings in Amgen were worth $7,713,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Laurel Wealth Advisors LLC boosted its stake in shares of Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares during the period. Norges Bank purchased a new stake in Amgen during the 2nd quarter valued at approximately $1,663,726,000. Vanguard Group Inc. raised its stake in Amgen by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after acquiring an additional 841,117 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after acquiring an additional 687,735 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Amgen by 128.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock valued at $332,017,000 after purchasing an additional 600,096 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ:AMGN opened at $332.93 on Friday. The firm’s fifty day simple moving average is $322.98 and its 200-day simple moving average is $301.63. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The stock has a market cap of $179.28 billion, a PE ratio of 25.73, a price-to-earnings-growth ratio of 3.10 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $257.05 and a fifty-two week high of $346.38.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same quarter last year, the business earned $5.58 earnings per share. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 73.57%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday. Wells Fargo & Company boosted their price objective on shares of Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a report on Tuesday, November 11th. Finally, Guggenheim increased their price target on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $332.85.

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,908 shares of company stock valued at $3,674,966 in the last ninety days. Corporate insiders own 0.76% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.